Geneos Wealth Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Geneos Wealth Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,400	Closed	-$6K	–	2420
2022 Q2	$6K	Hold	1,400	–	–	﹤0.01%	2138
2022 Q1	$12K	Hold	1,400	–	–	﹤0.01%	2014
2021 Q4	$19K	Hold	1,400	–	–	﹤0.01%	1911
2021 Q3	$29K	Hold	1,400	–	–	﹤0.01%	1740
2021 Q2	$17K	Hold	1,400	–	–	﹤0.01%	1996
2021 Q1	$14K	Hold	1,400	–	–	﹤0.01%	2239
2020 Q4	$14K	Buy	+1,400	New	+$4.56K	﹤0.01%	2082

Other funds holding ORMP

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geneos Wealth Management's ORMP Position: Q3 2022 in Review

Geneos Wealth Management sold out of Oramed Pharmaceuticals (ORMP) in Q3 2022, closing a stake of 1,400 shares — an estimated $6K sold.

Geneos Wealth Management first reported a position in ORMP in Q4 2020 and held it in 7 quarters. The position peaked at $29K in Q3 2021. 71 funds tracked by Wall St. Rank hold ORMP as of Q3 2022.

Geneos Wealth Management reported no remaining Oramed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Geneos Wealth Management sold 1,400 Oramed Pharmaceuticals shares in Q3 2022, an estimated $6K.
Geneos Wealth Management first reported a position in Oramed Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Geneos Wealth Management's Oramed Pharmaceuticals position peaked at $29K in Q3 2021.
71 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.